EA201300297A1 - LIQUID ANTI-VIRUS MEDICINE - Google Patents
LIQUID ANTI-VIRUS MEDICINEInfo
- Publication number
- EA201300297A1 EA201300297A1 EA201300297A EA201300297A EA201300297A1 EA 201300297 A1 EA201300297 A1 EA 201300297A1 EA 201300297 A EA201300297 A EA 201300297A EA 201300297 A EA201300297 A EA 201300297A EA 201300297 A1 EA201300297 A1 EA 201300297A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- buffer
- inf
- stabilizer
- alpha
- liquid drug
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к областям фармакологии и медицины и обеспечивает жидкое лекарственное средство, содержащее в качестве активного вещества ковалентный конъюгат интерферона-альфа (ИНФ-α) с полиэтиленгликолем (ПЭГ), буфер, стабилизатор и фармацевтически приемлемый растворитель, в котором ковалентный конъюгат является линейным или разветвлённым монопегилированным ИНФ-α общей формулы (I) или (II), стабилизатором является смесь сорбита, полисорбата 20 и L-глутамата натрия, буфером является цитратно-фосфатный буфер и фармацевтически приемлемым растворителем является вода. Техническим результатом изобретения является долговременная стабильность жидкого лекарственного средства с сохранением существенной доли активности немодифицированного интерферона-альфа, длительной циркуляцией в кровотоке и улучшенными характеристиками противовирусной активности и иммуногенности при хранении.The invention relates to the fields of pharmacology and medicine and provides a liquid drug containing as an active substance the covalent conjugate of interferon-alpha (INF-α) with polyethylene glycol (PEG), a buffer, a stabilizer and a pharmaceutically acceptable solvent, in which the covalent conjugate is linear or branched monopegylated INF-α of the general formula (I) or (II), the stabilizer is a mixture of sorbitol, polysorbate 20 and sodium L-glutamate, the buffer is citrate-phosphate buffer and pharmaceutically intake Solvent is water. The technical result of the invention is the long-term stability of the liquid drug with the preservation of a significant proportion of the activity of unmodified interferon-alpha, prolonged circulation in the bloodstream and improved characteristics of antiviral activity and immunogenicity during storage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201300297A EA021610B1 (en) | 2013-03-28 | 2013-03-28 | Liquid antiviral formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201300297A EA021610B1 (en) | 2013-03-28 | 2013-03-28 | Liquid antiviral formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201300297A1 true EA201300297A1 (en) | 2014-09-30 |
EA021610B1 EA021610B1 (en) | 2015-07-30 |
Family
ID=51628523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201300297A EA021610B1 (en) | 2013-03-28 | 2013-03-28 | Liquid antiviral formulation |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA021610B1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2101918A1 (en) * | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US8003117B2 (en) * | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
MXPA05010411A (en) * | 2003-03-28 | 2006-05-31 | Biopolymed Inc | Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same. |
WO2009030066A1 (en) * | 2007-09-04 | 2009-03-12 | Biosteed Gene Expression Tech. Co., Ltd. | Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
RU2447083C1 (en) * | 2010-07-20 | 2012-04-10 | Закрытое Акционерное Общество "Биокад" | NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON |
RU2433135C1 (en) * | 2010-10-06 | 2011-11-10 | Общество с ограниченной ответственностью "ФОРТ" | Interferon conjugated with polyethylene glycol |
-
2013
- 2013-03-28 EA EA201300297A patent/EA021610B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA021610B1 (en) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123597T1 (en) | INSULIN PREPARATION FOR QUICK RECRUITMENT | |
CY1122516T1 (en) | READY-TO-USE FORMULATIONS OF KETOROLAK | |
CU23734A1 (en) | IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES | |
AR068816A1 (en) | COMPOSITIONS OF BRIMONIDINE IMPROVED FOR THE TREATMENT OF ERYTHEMA | |
RU2016113283A (en) | Liquid protein formulations containing viscosity reducers | |
EA201492021A1 (en) | ANTI-COMPOSITION | |
CU23923B1 (en) | POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY | |
BR112015011179A8 (en) | stable aqueous pharmaceutical compositions comprising human insulin or an analogue or derivative thereof, their use and processes for their preparation | |
JP2016539921A5 (en) | ||
RU2010129824A (en) | NEW functionally active, highly purified, stable Alpha interferon conjugate with polyethylene glycol, represented by one of positional isomers of PEG-IFN-NAH with reduced immunogenicity, with a prolonged biological effect are suitable for medical applications, and immunobiological agent based on ITS | |
RU2016139373A (en) | Slow-Release Buprenorphine Solutions | |
IN2014MN01470A (en) | ||
PE20140134A1 (en) | METHODS TO IMPROVE OXYGENATION OF ENDANGERED TISSUE | |
CO7151496A2 (en) | Therapeutic agents for optimized subcutaneous administration | |
HRP20201696T1 (en) | Pharmaceutical parenteral formulation containing carglumic acid | |
CR20220546A (en) | Drug for treating coronaviral and retroviral infections and hepatitis c | |
EA201300297A1 (en) | LIQUID ANTI-VIRUS MEDICINE | |
RU2013146452A (en) | INJECTION OR INFUSION TRIAZAVIRINE SOLUTION FOR TREATING VIRAL INFECTIONS | |
NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
RU2010114841A (en) | SELF-CONTAINING DRUG FOR PREVENTION AND TREATMENT OF MICROELEMENTOSIS IN AGRICULTURAL ANIMALS AND BIRDS | |
AR082806A1 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
EA201491841A1 (en) | COMPOSITION OF ESMOLOL FOR PARENTERAL INTRODUCTION | |
EA201101663A1 (en) | COVALENT CONJUGATE OF POLYETHYLENE GLYCOL WITH GRANULOCITARIAN COLONIUS STIMULATING FACTOR OF THE PERSON | |
RU2020109402A (en) | GLP-1 BASED COMPOSITIONS AND WAYS OF THEIR APPLICATION | |
BR112017012975A2 (en) | injectable paracetamol formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG TJ TM |